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Abstract 
Background: The aim of the study was to evaluate the prognostic ability of the transcriptional profiling of the HER 
family genes in early breast cancer, as a validation analysis of another previously published HeCOG study.
Methods: RNA was extracted from 663 formalin-fixed paraffin-embedded (FFPE) tumor tissue samples of high-risk 
early breast cancer patients enrolled in the randomized HE10/00 trial. Relative mRNA expression of all four HER family 
members was assessed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Results: In compliance with our previous study, the overall agreement between qRT-PCR and IHC/FISH for HER2 
status determination was good (69%). Likewise, the overall concordance between qRT-PCR and IHC for EGFR status 
was high (81%). In line with our previously reported data, we demonstrated a positive association between HER2 and 
HER3 mRNA expression. Similarly, mRNA expression of HER3 and HER4 was positively associated with each other and 
negatively associated with EGFR. Regarding relationships with clinico-pathological parameters, our findings are also in 
agreement with our previous results. Generally, increased EGFR and HER2 mRNA expression was related to unfavora-
ble, whereas high HER3 and HER4 mRNA expression was associated with favorable clinico-pathological parameters. 
In univariate analysis, no significant association between EGFR, HER2 and HER3 mRNA expression and overall survival 
(OS) or disease-free survival (DFS) was demonstrated. However, high EGFR protein expression was associated with sig-
nificantly shorter OS (log-rank, p = 0.015). In compliance with our previously published data, increased HER4 mRNA 
expression had a significantly favorable prognostic value in terms of OS (p = 0.044) and DFS (p = 0.047). In multivari-
ate analysis, among all HER receptors, only EGFR protein expression was found to affect OS (Wald’s p = 0.028) and DFS 
(p = 0.015) independently. Concerning the combined expression of all four HER family receptors, the combination of 
high EGFR, high HER2, low HER3 and low HER4 mRNA expression was associated with a trend for shorter OS (log-rank, 
p = 0.065) and significantly worse DFS (p = 0.033), compared with all other co-expression profiles.
Conclusions: These data indicate that qRT-PCR may represent a valid alternative method for evaluating the expres-
sion of HER family members in FFPE breast carcinoma tissue samples.
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Background
The human epidermal growth factor receptor (HER) fam-
ily consists of four homologous members: ErbB-1 (epi-
dermal growth factor receptor [EGFR] or HER1), ErbB-2 
(HER2), ErbB-3 (HER3) and ErbB-4 (HER4) [1]. The HER 
family constitutes a promising area for the development 
of targeted treatments in patients with breast cancer 
and considerable therapeutic progress has already been 
achieved. Apart from HER2, the significance of lateral 
signaling partners is also increasingly recognized, given 
the role of dimerization among HER receptors. There-
fore, the evaluation of all HER family members as a whole 
is considered important.
Overexpression and/or amplification of the HER2 
receptor occurs in 15–30% of breast cancer cases and is 
associated with aggressive course of the disease and unfa-
vorable clinical outcome [2]. HER2 status can be evaluated 
at the DNA, the mRNA or the protein level. Although 
various assays are available, immunohistochemistry (IHC) 
is the technique of choice in the routine practice. Fluo-
rescence in situ hybridization (FISH) analysis is required 
in cases with (2+) HER2 immunostaining [3]. However, 
despite efforts to standardize these techniques, there is a 
considerable intra- and inter-laboratory variability of the 
results [4, 5]. Quantitative reverse transcription-polymer-
ase chain reaction (qRT-PCR) represents an alternative 
test for the determination of HER2 status. qRT-PCR does 
not necessitate experienced pathologists to interpret the 
results and is associated with reproducible and quantita-
tive findings. Previous reports have demonstrated that the 
qRT-PCR can be applied in archival formalin-fixed paraf-
fin-embedded (FFPE) tissues [6].
In a previous study [7], we investigated the potential 
prognostic value of the transcriptional profiling of all four 
HER family genes in patients with high-risk early breast 
cancer, receiving dose-dense anthracycline-based sequen-
tial adjuvant chemotherapy with or without paclitaxel. 
The results of this analysis, using qRT-PCR, suggested that 
EGFR and HER2 are unfavorable prognostic markers, while 
HER3 and HER4 mRNA expression is related to better clin-
ical outcome. In order to validate the above findings in the 
current study, we evaluated the prognostic ability of HER 
family mRNA expression using qRT-PCR, in a larger series 
of high-risk patients with early breast cancer. These patients 
were treated with dose-dense sequential or concurrent epi-
rubicin and paclitaxel, followed by ‘intensified’ CMF, within 
the context of the Hellenic Cooperative Oncology Group 
(HeCOG) 10/00 randomized phase III trial [8].
Methods
Clinical study
The HE10/00 trial [8] was a randomized phase III study 
(ACTRN12609001036202). Patients were treated with 
three cycles of epirubicin (E), followed by three cycles of 
paclitaxel (T, Taxol, Bristol Myers-Squibb, Princeton, NJ), 
followed by three cycles of intensified CMF (cyclophos-
phamide, methotrexate and 5-fluorouracil) (E–T–CMF, 
all cycles given every 2 weeks) or with four cycles of epi-
rubicin/paclitaxel (ET) combination (given on the same 
day every 3  weeks) followed by three cycles of intensi-
fied CMF every 2 weeks (ET–CMF). By study design, the 
cumulative doses and the chemotherapy duration were 
identical in the two arms but dose intensity of epirubicin 
and paclitaxel was double in the E–T–CMF arm. A total 
of 1,086 eligible patients with node-positive operable 
breast cancer were accrued in a period of 5 years (2000–
2005). HER2-positive patients received trastuzumab 
upon relapse, as previously described [9]. Treatment 
schedules, baseline characteristics and clinical outcomes 
have already been described in detail [8]. Primary tumor 
diameter, axillary nodal status and tumor grade were 
obtained from the pathology report. The clinical proto-
col was approved by local regulatory authorities, while 
the present translational research studies were approved 
by the Bioethics Committee of the Aristotle University 
of Thessaloniki School of Medicine. All patients signed a 
study-specific written informed consent before randomi-
zation, which in addition to giving consent for the trial 
allowed the use of biological material for future research 
purposes.
Tissue microarray (TMA) construction
Formalin-fixed paraffin-embedded (FFPE) tumor tissue 
samples were prospectively collected from 663 patients 
(61% of 1,086 randomized patients) who were part of the 
HE10/00 study population. For 39% of the randomized 
patients, we were either not successful in obtaining an 
FFPE tumor tissue sample or the sample obtained was 
not of adequate quality or quantity for biomarker evalu-
ation. The REMARK diagram [10] for the study is shown 
in Figure 1. Hematoxylin–eosin stained sections from the 
tissue blocks were reviewed by two experienced breast 
cancer pathologists and the most representative tumor 
areas were marked for the construction of the ΤΜΑ blocks 
with the use of a manual arrayer (Model I, Beecher Instru-
ments, San Prairie, WI), as previously described [11, 12]. 
Each case was represented by two tissue cores, 1.5 mm in 
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diameter, obtained from the most representative areas of 
primary invasive tumors or in some cases (7.2%) from syn-
chronous axillary lymph node metastases and re-embed-
ded in 35 microarray blocks. Each TMA block contained 
38–66 tissue cores from the original tumor tissue blocks, 
while cores from various neoplastic, non-neoplastic and 
reactive tissues were also included, serving as controls 
for slide-based assays. Cases not represented, damaged 
or inadequate on the TMA sections were re-cut from 
the original blocks and these sections were used for pro-
tein and gene analysis. Histological grade was evaluated 
according to the Scarff, Bloom and Richardson system.
Immunohistochemistry (IHC)
Immunohistochemical labeling was performed accord-
ing to standard protocols on serial 2.5 μm thick sections 
from the TMA blocks or the original blocks. All cases 
were also stained for vimentin (clone V9, Dako, Glostrup, 
Denmark) and cytokeratin 8/18 (clone 5D3, Novocastra™, 
Leica Biosystems, Newcastle, UK), which were used as 
control stains for tissue immunoreactivity and fixation, 
as well as identification of tumor cells. Tissue samples 
negative for the above antibodies were excluded from 
the study. To assure optimal reactivity, immunostain-
ing was done 7–10  days after sectioning at the Labora-
tory of Molecular Oncology of the Hellenic Foundation 
for Cancer Research, Aristotle University of Thessaloniki 
School of Medicine. The staining procedures for EGFR 
(clone 31G7, Invitrogen, Carlsbad, CA), HER2 (A0485 
polyclonal antibody, Dako), estrogen receptor (ER, clone 
6F11, Novocastra™, Leica Biosystems), progesterone 
receptor (PgR, clone 1A6, Novocastra™, Leica Biosys-
tems) and Ki67 (clone MIB-1, Dako) were performed 
using a Bond Max™ autostainer (Leica Microsystems, 
Wetzlar, Germany), as previously described [13].
Interpretation of the IHC results
The evaluation of all IHC sections was done by two 
experienced breast cancer pathologists, blinded as to 
the patients’ clinical characteristics and survival data, 
according to existing established criteria, as previously 
described [9]. Briefly, EGFR protein expression was 
scored in a scale from 0 to 3+ and was considered to be 
positive if membraneous staining of 1+, 2+ or 3+ was 
present in ≥1% of tumor cells [14]; HER2 protein expres-
sion was scored in a scale from 0 to 3+, the latter cor-
responding to uniform, intense membrane staining in 
>30% of invasive tumor cells [15]; ER and PgR were eval-
uated using the Histoscore method (max score 400) and 
were considered positive if staining was present in ≥1% 
of tumor cell nuclei [16] and, for Ki67, the expression 
was defined as low (<14%) or high (≥14%) based on the 
percentage of stained tumor cell nuclei [17]. The mean 
percentage of stained cells from the two cores was calcu-
lated, while in cases with different intensities, the higher 
intensity score obtained from the two cores was used. If 
one of the tissue cores was lost or damaged the overall 
score was determined from the remaining one. When 
whole tissue sections were used, the entire tumor area 
was evaluated.
Fluorescence in situ hybridization (FISH)
TMA sections or whole sections (5  μm thick) were 
cut for FISH analysis, using the ZytoLight® SPEC 
HER2/TOP2A/CEP17 triple-color probe kit (ZytoVi-
sion, Bremerhaven, Germany). The FISH was performed 
according to the manufacturer’s protocol with minor 
modifications. Four carcinoma cell lines (MDA-MB-231, 
MDA-MB-175, MDA-MB-453 and SK-BR-3) from the 
Oracle HER2 Control Slide (Leica Biosystems), with a 
known HER2 gene status, were also used as a control for 
the FISH assays and analyzed for HER2 genomic status.
For all probes, sequential (5 planes at 1.0 μm) digital 
images were captured using the Plan Apo VC 100×/1.40 
Figure 1 REMARK diagram.
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oil objective (Nikon, Kanagawa, Japan), using spe-
cific filters for each probe. The resulting images were 
reconstructed using specifically developed software for 
cytogenetics (XCyto-Gen, ALPHELYS, Plaisir, France). 
Processed sections were considered eligible for FISH 
evaluation according to the ASCO/CAP criteria [15]. For 
the evaluation of HER2/TOP2A/CEP17 status, non-over-
lapping nuclei from the invasive part of the tumor were 
randomly selected, according to morphological criteria 
using DAPI staining, and scored. The virtual slides of 
HER2, ER or PgR stains, created as previously described 
[13] were used for selecting the invasive part of the tumor 
in each TMA. Twenty tumor nuclei were counted accord-
ing to Press et al. [18]. The HER2 gene was considered to 
be amplified when the HER2/CEP17 ratio was ≥2.2 [15], 
or the mean HER2 copy number was >6 [19].
In cases with ratios at or near the cut-off (1.8–2.2), 
additional 20 or 40 nuclei were counted and the ratio was 
recalculated. In cases with a borderline ratio at 60 nuclei, 
additional FISH assays were performed in whole sec-
tions [20]. All primary image data of the TMA and whole 
tumor sections have been digitally scanned and made 
publicly available at: http://www.hecog-images.gr/HER2/
TOP2A/CEN17/FISH_HE10/97_HE10/00.
RNA isolation from FFPE tissue and quantitative reverse 
transcription‑polymerase chain reaction (qRT‑PCR) 
assessment
Prior to RNA isolation, macrodissection of tumor areas 
was performed in most of the FFPE sections with <50% 
tumor cell content. More than one FFPE section (10 μm 
thick) was used for RNA extraction when the tumor sur-
face of a given sample was less than 0.25 cm2. From each 
FFPE section or macrodissected tissue fragments, RNA 
was extracted using a standardized fully automated iso-
lation method for total RNA from FFPE tissue, based 
on germanium-coated magnetic beads (XTRAKT kit, 
STRATIFYER Molecular Pathology GmbH, Cologne, 
Germany) in combination with a liquid handling 
robot (XTRAKT XL, STRATIFYER Molecular Pathol-
ogy GmbH), as previously described [21]. The method 
involves extraction-integrated deparaffinization and 
DNase I digestion steps. The quality and quantity of RNA 
was checked by measuring CALM2 expression as a sur-
rogate for amplifiable mRNA by qRT-PCR. CALM2 was 
used as endogenous reference, since it had previously 
been identified as being highly expressed among breast 
cancer tissue samples.
qRT-PCR primers and labeled hydrolysis probes were 
selected using Primer Express® Software, Version 2.2 and 
3 (Applied Biosystems/Life Technologies, Karlsruhe, Ger-
many), according to the manufacturer’s instructions, and 
were controlled for single nucleotide polymorphisms. All 
primers, probes and amplicons were checked for their 
specificity against nucleotide databases at NCBI using 
basic local alignment search tool (BLAST). Primers and 
probes were purchased from Eurogentec S.A. (Seraing, 
Belgium). For each primer/probe set, the amplification 
efficiency was tested, aiming to reach comparable effi-
ciency of >90% (efficiency range from 91 to 100%). Prim-
ers and hydrolysis probes were diluted to 100 µM, using 
a stock solution with nuclease-free water (Life Technolo-
gies GmbH, Darmstadt, Germany). qRT-PCR was applied 
for the relative quantification (RQ) of the HER family 
genes EGFR, HER2, HER3 and HER4. The Primer/probe 
(FAM/TAMRA-labeled) sets used for amplification of the 
target and reference genes are shown in Table 1.
For PCR, 0.5 µM of each primer and 0.25 µM of each 
probe were used. All quantitative reverse-transcription 
PCRs were performed in triplicates using the Super-
Script® III Platinum® One-Step qRT-PCR kit (Invitrogen/
Life Technologies, Darmstadt, Germany) according to 
the manufacturer’s instructions. Experiments were per-
formed on a Stratagene Mx3005p (Agilent Technolo-
gies, Waldbronn, Germany) with 30  min at 50°C and 
2 min at 95°C followed by 40 cycles of 15 s at 95°C and 
Table 1 Primer and probe sequences used for quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Gene symbol NM_number Probe name Probe sequence Forward name Forward sequence Reverse name Reverse sequence
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30  s at 60°C. The lengths of the amplicons detected by 
the EGFR, HER2, HER3, HER4 and CALM2 assays were 
93, 61, 81, 75 and 72 bp, respectively, with PCR efficien-
cies [E = 1(10 −  slope)] of 89.1, 97.2, 96.0, 92.0 and 99.7%, 
respectively. Samples were considered eligible for further 
investigation when the cycle threshold (CT) values of the 
housekeeping gene were <32 (triplicate mean values). 
Relative expression levels (relative quantification, RQ) of 
the target transcripts were calculated as 40—DCT values 
(DCT =  mean CT target gene −  mean CT housekeep-
ing gene) to yield positively correlated numbers and to 
facilitate comparisons. A commercially available human 
reference RNA (Stratagene qPCR Human Reference 
Total RNA, Agilent Technologies, Waldbronn, Germany) 
was used as positive control. No-template controls were 
assessed in parallel to exclude contamination.
Statistical analysis
Continuous data are presented as medians and corre-
sponding ranges, while categorical data are presented as 
counts and percentages. Separation of continuous mark-
ers into high and low expression was performed using 
predetermined cut-offs based on a previously published 
study [7]. These cut-offs were the 75th percentile for 
EGFR and the 50th percentile, or the median as it is usu-
ally referred to, for HER2, HER3 and HER4. The Spear-
man’s correlation coefficient method was used to assess 
correlations among continuous variables.
Comparisons of categorical with continuous variables 
were made using the Mann–Whitney or the Kruskal–
Wallis tests, while the Chi square test was used for test-
ing associations between categorical variables. Cohen’s 
Kappa and calculation of sensitivity and specificity were 
used as assessing tools in order to determine the con-
cordance between the qRT-PCR and IHC/FISH methods.
Disease-free survival (DFS) was measured from the 
date of diagnosis until verified disease progression, death 
or last contact (whichever occurred first), while overall 
survival (OS) was measured from the date of diagnosis 
until death from any cause or date of last contact. Time-
to-event distributions were estimated using Kaplan–
Meier curves, while log-rank tests and univariate Cox 
analyses were used for assessing differences statistically. 
Possible prognostic significance of the markers among 
breast tumor subtypes was assessed using univariate Cox 
analyses with interactions. Univariate tests were deter-
mined at the level of 0.1%, controlling for multiple com-
parisons and keeping the overall type I error rate at the 
level of 5%. Due to the exploratory nature of this study, 
p values less than 0.05 were presented in the results 
section.
In the multivariate Cox regression analysis, signifi-
cance was determined at the level of 15%, while variable 
selection was performed based on the likelihood ratio 
test, among the following factors: number of positive 
nodes, tumor size, type of surgery, adjuvant radiotherapy, 
adjuvant hormonal therapy and subtype classification. 
All tests were two-sided. The statistical analysis complied 
with the reporting recommendations for tumor marker 
prognostic studies (REMARK) [10] and was performed 
using the SAS software (SAS for Windows, version 9.3, 
SAS Institute Inc., Cary, NC).
Results
Study population
Basic patient and tumor characteristics according to 
treatment arm and in the entire study population are 
shown in Table 2. The differences among these character-
istics between the cohort of 663 patients included in the 
analysis and the remaining 423 patients of the HE10/00 
study that were not included are shown in Table 3. The 
cohort of patients used in the current analysis included 
cases with more aggressive characteristics, such as higher 
histological grade, higher number of positive nodes and 
tumor size, with higher histological grade being found to 
be associated with HER2 status (66% in HER2-positive 
vs. 46% in HER2-negative patients, p < 0.001).
Relative mRNA expression values of HER family receptors
The distribution of relative expression values (2 to the 
power of DCT) of mRNA encoding for HER family mem-
bers is shown in Figure  2. The median value for EGFR 
was 421.7 (range 1–38,431), for HER2 1.3 (range 0.02–
2,256), for HER3 1.2 (range 0.01–73.1) and for HER4 10.7 
(range 0.12–53,231).
Concordance between qRT‑PCR and IHC
The total number of samples with data available from 
both IHC/FISH and qRT-PCR was 625 and 632 for EGFR 
and HER2, respectively. For EGFR, 93 of the 625 tumors 
(14.9%) were IHC positive, whereas 153 tumors (24.5%) 
had EGFR mRNA expression at or above the 75th per-
centile, as assessed by qRT-PCR. For HER2, 143 of the 
632 tumors (22.6%) were IHC/FISH positive, whereas 
316 tumors (50.0%) had HER2 mRNA expression at or 
above the median, as assessed by qRT-PCR. For these 
tumors, we found a statistically significant association 
between the evaluations obtained by the two methods, 
for the EGFR (Chi square test, p < 0.001) and the HER2 
(Chi square test, p < 0.001) receptors. The observed over-
all concordance between the determination of HER2 by 
qRT-PCR and IHC/FISH was 69.1%. The levels for sen-
sitivity and specificity were 92.3 and 62.4%, respectively, 
while Cohen’s kappa was 0.38 (95% CI 0.32–0.44). The 
overall agreement between qRT-PCR and IHC for EGFR 
was 80.8%. Sensitivity and specificity were 67.7 and 
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 N 324 339 663
Age in years
 Mean (SD) 54.2 (11.1) 53.9 (11.3) 54.0 (11.2)
 Min–Max 29–79 22–76 22–79
N (%) N (%) N (%)
Adjuvant hormonal therapy
 Yes 234 (74.3) 252 (77.3) 486 (75.8)
 No 81 (25.7) 74 (22.7) 155 (24.2)
 Not reported 9 (2.8) 13 (3.8) 22 (3.3)
Adjuvant radiotherapy
 Yes 220 (71.0) 260 (80.0) 480 (75.6)
 No 90 (29.0) 65 (20.0) 155 (24.4)
 Not reported 14 (4.3) 14 (4.1) 28 (4.2)
Age
 <50 117 (36.1) 123 (36.2) 240 (36.2)
 ≥50 207 (63.9) 216 (63.8) 423 (63.8)
EGFR protein expression
 Positive 50 (15.9) 46 (14.4) 96 (15.2)
 Negative (<1%) 264 (84.1) 273 (85.6) 537 (84.8)
 Not reported 10 (3.1) 20 (5.9) 30 (4.5)
ER/PgR status
 Negative 84 (26.0) 85 (25.1) 169 (25.5)
 Positive 239 (74.0) 254 (74.9) 493 (74.5)
 Not reported 1 (0.3) 1 (0.2)
Histological grade
 I–II 154 (47.5) 172 (50.8) 326 (49.2)
 III-undifferentiated 170 (52.5) 167 (49.2) 337 (50.8)
HER2 protein expression
 Overexpression 92 (29.3) 103 (31.5) 195 (30.4)
 No overexpression 222 (70.7) 224 (68.5) 446 (69.6)
 Not reported 10 (3.1) 12 (3.5) 22 (3.3)
HER2 status (IHC/FISH)
 Negative 241 (77.5) 248 (77.3) 489 (77.4)
 Positive 70 (22.5) 73 (22.7) 143 (22.6)
 Not reported 13 (4.0) 18 (5.3) 31 (4.7)
Histological type
 Invasive ductal 261 (80.6) 268 (79.1) 529 (79.8)
 Invasive lobular 27 (8.3) 37 (10.9) 64 (9.6)
 Mixed 22 (6.8) 19 (5.6) 41 (6.2)
Other 14 (4.3) 15 (4.4) 29 (4.4)
Interval from operation
 <2 weeks 27 (8.3) 22 (6.5) 49 (7.4)
 2–4 weeks 144 (44.6) 147 (43.5) 291 (44.0)
 >4 weeks 152 (47.1) 169 (50.0) 321 (48.6)
 Not reported 1 (0.3) 1 (0.3) 2 (0.3)
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83.1%, respectively, while Cohen’s kappa was 0.40 (95% 
CI 0.32–0.49) (Table 4).
Relationships among HER family receptor mRNA 
expression
A positive correlation was demonstrated between HER2 
and HER3 mRNA expression levels (r = 0.42, p < 0.0001), 
as well as between HER2 and HER4 mRNA values 
(r  =  0.11, p  =  0.007). Furthermore, HER3 and HER4 
mRNA expression levels were positively correlated to 
each other (r = 0.56, p < 0.0001) and negatively so with 
EGFR (r = −0.16, p < 0.0001 and r = −0.15, p < 0.0001, 
respectively). Scattered plots of the mRNA expression 
values of different HER family members are presented in 
Figure 3.
Association of HER family receptor mRNA expression 
with clinicopathological parameters
EGFR mRNA expression was inversely associated with 
the presence of ER (Mann–Whitney, p < 0.001) and PgR 
(p  =  0.005). Moreover, EGFR mRNA expression was 
inversely related to age (p  =  0.003), post-menopausal 
status (p =  0.003) and tumor size (p =  0.001). A nega-
tive correlation between HER2 mRNA expression and 
PgR was found (p  =  0.003). HER3 mRNA expression 
was associated with ER (p  <  0.001) and PgR positiv-
ity (p  <  0.001), as well as with histological grade I/II 
(p  =  0.001). In addition, HER3 mRNA expression was 
inversely related to the number of positive lymph nodes 
(p = 0.017). HER4 mRNA expression was correlated with 
ER and PgR positivity (p < 0.001 and p < 0.001, respec-
tively), as well as with histological grade I/II (Kruskal–
Wallis, p  <  0.001). Furthermore, HER4 was associated 
with lobular and mixed histology (p = 0.002).
Regarding the associations of HER family receptor 
mRNA expression with breast cancer subtypes, high 
EGFR mRNA expression was associated with triple-
negative breast cancer (TNBC) (p  <  0.001), while high 
HER2 mRNA expression with luminal-HER2 and HER2-
enriched subtypes (both, p < 0.001). High HER3 mRNA 
expression was associated with luminal A and luminal B 
subtypes (both, p  <  0.001), whereas high HER4 mRNA 
expression with luminal A tumors (p < 0.001).
Prognostic value of HER family receptor mRNA expression
Survival status of the patients was updated in March 
2012. The median follow-up time was 98.9  months 
(range 0.1–132.5 months). During this time, 218 patients 
(32.9%) had developed a relapse and 151 patients (22.8%) 
had died. The 8-year OS was 78.2%, whereas the 8-year 
DFS was 68.5%. The median OS and DFS have not been 
reached yet.
Concerning patients with high EGFR mRNA expres-
sion, a trend for significantly reduced OS (HR = 1.38, 95% 
CI 0.98–1.96, Wald’s p = 0.068, log-rank p = 0.074) was 
observed. However, with respect to protein expression, 
Patient characteristics were well balanced between the two arms.
Table 2 continued
N (%) N (%) N (%)
Menopausal status
 Pre 137 (42.3) 145 (42.8) 282 (42.6)
 Post 187 (57.7) 194 (57.2) 381 (57.4)
Number of positive nodes
 1–3 143 (44.1) 159 (46.9) 302 (45.6)
 ≥4 181 (55.9) 180 (53.1) 361 (54.4)
Tumor size
 ≤2 cm 90 (27.8) 107 (31.6) 197 (29.8)
 >2 cm 234 (72.2) 232 (68.4) 466 (70.2)
Subtype classification
 Luminal A 93 (30.5) 97 (30.3) 190 (30.4)
 Luminal B 105 (34.4) 112 (35.0) 217 (34.7)
 Luminal-HER2 35 (11.5) 44 (13.7) 79 (12.6)
 HER2-enriched 35 (11.5) 29 (9.1) 64 (10.3)
 Triple-negative 37 (12.1) 38 (11.9) 75 (12.0)
 Not reported 19 (5.9) 19 (5.6) 38 (5.7)
Type of surgery
 Modified radical mastectomy 219 (67.6) 227 (67.0) 446 (67.3)
 Breast-conserving 105 (32.4) 112 (33.0) 217 (32.7)
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Table 3 Basic patient and tumor characteristics in cases included and not included in the analysis
Entire HE10/00 cohort: 1,086 patients Included (N = 663) Not included (N = 423) p value
N (%) N (%)
Adjuvant hormonal therapy
 Yes 486 (75.8) 293 (73.3) 0.35
 No 155 (24.2) 107 (26.7)
Adjuvant radiotherapy
 Yes 480 (75.6) 296 (73.8) 0.52
 No 155 (24.4) 105 (26.2)
Age
 <50 240 (36.2) 195 (46.2) 0.001
 ≥50 423 (63.8) 227 (53.8)
EGFR protein expression
 Positive 96 (15.2) 22 (17.5) 0.52
 Negative (<1%) 537 (84.8) 104 (82.5)
ER/PgR status
 Negative 169 (25.5) 116 (27.5) 0.48
 Positive 493 (74.5) 306 (72.5)
Histological grade
 I–II 326 (49.2) 237 (56.3) 0.022
 III-undifferentiated 337 (50.8) 184 (43.7)
HER2 protein expression
 Overexpression 195 (30.4) 165 (40.6) 0.001
 No overexpression 446 (69.6) 241 (59.4)
HER2 status (IHC/FISH)
 Negative 489 (77.4) 98 (73.1) 0.29
 Positive 143 (22.6) 36 (26.9)
Histological type
 Invasive ductal 529 (79.7) 323 (76.5) 0.18
 Invasive lobular 64 (9.7) 45 (10.7)
 Mixed 41 (6.2) 23 (5.5)
 Other 29 (4.4) 31 (7.3)
Interval from operation
 <2 weeks 49 (7.4) 33 (7.9) 0.79
 2–4 weeks 291 (44.0) 192 (45.7)
 >4 weeks 321 (48.6) 195 (46.4)
Menopausal status
 Pre 282 (42.5) 220 (52.0) 0.002
 Post 381 (57.5) 203 (48.0)
Number of positive nodes
 1–3 302 (45.6) 224 (53.0) 0.017
 ≥4 361 (54.4) 199 (47.0)
Tumor size
 ≤2 cm 197 (29.7) 149 (35.5) 0.048
 >2 cm 466 (70.3) 271 (64.5)
Subtype classification
 Luminal A 190 (30.4) 34 (27.6) 0.40
 Luminal B 217 (34.7) 35 (28.5)
 Luminal-HER2 79 (12.7) 21 (17.1)
 HER2-enriched 64 (10.2) 14 (11.4)
 Triple-negative 75 (12.0) 19 (15.4)
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patients whose tumors were positive for EGFR had signif-
icantly reduced OS (HR = 1.65, 95% CI 1.10–2.48, Wald’s 
p = 0.017, log-rank p = 0.015) (Figure 4). No significant 
associations between HER2 (either mRNA expression 
or HER2 status by IHC/FISH) and OS were found. Simi-
larly, HER3 mRNA expression was not associated with 
OS. In contrast, high HER4 mRNA expression (using the 
median value as a cut-off point) had a favorable prognos-
tic value in terms of OS (HR = 0.72, 95% CI 0.52–0.99, 
Wald’s p = 0.045, log-rank p = 0.044) (Figure 5). In the 
multivariate analysis that included 612 patients, EGFR 
protein expression (HR = 1.66, 95% CI 1.06–2.60, Wald’s 
Significant p values are shown in bold.
Table 3 continued
Entire HE10/00 cohort: 1,086 patients Included (N = 663) Not included (N = 423) p value
N (%) N (%)
Type of surgery
 Modified radical mastectomy 446 (67.3) 262 (62.1) 0.080
 Breast-conserving 217 (32.7) 160 (37.9)
Figure 2 Distribution of relative expression values of mRNA encoding for HER family receptors. The 2 to the power of DCT method was used for 
data calculation. CT cycle threshold, DCT delta CT, RQ relative quantification.
Table 4 Comparison of EGFR and HER2 mRNA expression with EGFR protein expression and HER2 status, respectively
NPV negative predictive value, PPV positive predictive value.
EGFR mRNA  
(cut‑off at 75%)
EGFR protein expression (N = 625) NPV/PPV (%) Sensitivity (%) Specificity 
(%)
Negative Positive
Low 442 (83.1%) 30 (32.3%) 93.6/41.2 67.7 83.1
High 90 (16.9%) 63 (67.7%)
HER2 mRNA  
(cut‑off at 50%)
HER2 (IHC/FISH) (N = 632) NPV/PPV (%) Sensitivity (%) Specificity 
(%)
Negative Positive
Low 305 (62.4%) 11 (7.7%) 96.5/41.8 92.3 62.4
High 184 (37.6%) 132 (92.3%)
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p  =  0.028), tumor size (HR  =  1.60, 95% CI 1.07–2.40, 
p = 0.023) and the number of positive nodes (HR = 2.74, 
95% CI 1.86–4.04, p  <  0.001) retained their prognostic 
significance for OS (Table 5).
With respect to DFS, no significant associations were 
demonstrated for EGFR, HER2 or HER3 mRNA expres-
sion. On the other hand, high HER4 mRNA expression was 
associated with lower risk for relapse (HR = 0.76, 95% CI 
0.59–1.00, Wald’s p = 0.048, log-rank p = 0.047) (Figure 5). 
However, in multivariate analysis only EGFR protein expres-
sion (HR = 1.56, 95% CI 1.09–2.24, Wald’s p = 0.015), type 
of surgery (HR = 1.49, 95% CI 1.07–2.06, p = 0.017) and the 
number of positive nodes (HR =  2.13, 95% CI 1.58–2.87, 
p < 0.001) independently affected DFS (Table 5).
Prognostic value of HER family receptor mRNA expression 
among subtypes
The prognostic significance of the HER family recep-
tor mRNA expression among breast cancer subtypes 
was assessed by the use of univariate interaction tests. 
High EGFR mRNA expression was found to have unfa-
vorable prognostic value in HER2-enriched cases in 
terms of OS (HR =  5.30, 95% CI 1.71–16.45, interac-
tion p = 0.031). Adjusting for basic clinical and treat-
ment characteristics, the prognostic ability of EGFR 
mRNA expression remained significant for OS, not 
only for the HER2-enriched tumors (HR =  9.12, 95% 
CI 2.87–29.03, Wald’s p  =  0.0002), but also for the 
triple-negative patients (HR = 2.32, 95% CI 1.02–5.27, 
p = 0.045), with an overall interaction p value of 0.003 
(data not shown).
Prognostic value of HER family member co‑expression
Regarding the prognostic significance of specific co-
expression patterns of all four HER family receptors, we 
found that the combination of high EGFR, high HER2, 
low HER3, and low HER4 mRNA expression was associ-
ated with significantly worse DFS (log-rank, p =  0.033) 
and a trend for decreased OS (p = 0.065), compared with 
all other possible co-expression profiles.
Figure 3 Scattered plots of mRNA expression values (40-DCT) of different HER family members. a HER2 vs. HER3; b HER2 vs. HER4; c HER3 vs. EGFR; 
and d HER3 vs. HER4. CT cycle threshold, DCT delta CT.
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Discussion
In the current study, we used qRT-PCR to evaluate the 
transcriptional profiling of all four HER family receptor 
genes, in a large series of high-risk (predominantly T2-3, 
node-positive) early breast cancer patients, with a sub-
stantially long follow-up of 8 years. The aim of this analy-
sis was to validate the findings of a previously published 
similar study, conducted from our group [7]. Most of the 
available studies have assessed protein expression and/
or gene amplification of specific HER family members. 
Therefore, the prognosis of patients with breast cancer 
relating to the transcriptional profiling of all HER family 
receptors has not been extensively evaluated.
In accord with our previous results, the overall agree-
ment between qRT-PCR (using the 50th percentile cut-
off) and IHC/FISH for the determination of HER2 status 
was good (69%), with a Cohen’s kappa value of only 0.38, 
due to inherent differences in the cut-offs used in the 
two methods. These findings are in line with other stud-
ies [6, 22, 23]. Similarly, in agreement with our previous 
study the overall concordance between qRT-PCR (using 
the 75th percentile cut-off) and IHC for the evaluation 
of EGFR status was high (81%). Moreover, in complete 
agreement with our previous results, the qRT-PCR tech-
nique for HER2 (using the median value as a threshold) 
was associated with a high level of sensitivity (92%) and 
acceptable specificity (62%). The limitations regarding 
qRT-PCR as an alternative method for assessing HER 
family members in FFPE samples has previously been 
described [7].
Concerning the associations with clinicopathological 
parameters, our results are in compliance with our previ-
ous findings, as well. In general, HER3 and HER4 mRNA 
expression was associated with favorable, while EGFR 
Figure 4 Overall survival according to EGFR protein and mRNA expression.
Page 12 of 15Koutras et al. J Transl Med  (2015) 13:171 
and HER2 mRNA expression was associated with unfa-
vorable parameters.
In the prognostic analyses, no significant associations 
between EGFR mRNA expression and OS were found in 
the total population, irrespectively of the cut-off points 
that we used. In our previous study [7], we demonstrated 
a reduced OS in patients with increased EGFR mRNA 
expression, using the 75th percentile as a cut-off. In the 
present analysis using the same cut-off, a trend (p = 0.074) 
towards a decreased OS was shown. Evaluating treatment 
arms separately, the difference in OS using the 75th per-
centile was significant in patients receiving the E–T–CMF 
regimen (p = 0.044). Moreover, EGFR mRNA expression 
was found to be a significant negative prognostic factor 
for OS in HER2-enriched and TNBC cases.
With regard to protein expression, patients with 
tumors positive for EGFR had significantly shorter OS in 
the total study population. Moreover, the negative prog-
nostic significance of EGFR protein expression for OS 
and DFS was demonstrated in the multivariate analysis of 
the study. EGFR is considered to be a negative prognostic 
factor in breast cancer and such an association has been 
shown in ours, as well as in other studies [24–27].
In contrast to our previously reported data [7] and 
other studies [23, 28] no significant associations between 
HER2 status (either by mRNA expression or IHC/FISH) 
and OS or DFS were demonstrated. A definitive expla-
nation for this unexpected finding cannot be given. 
Although adjuvant treatment with trastuzumab could 
be proposed to be a possible reason, none of the patients 
enrolled in the HE10/00 phase III trial received adjuvant 
therapy with trastuzumab. On the other hand, all patients 
had been treated with paclitaxel. So far, data concern-
ing the interaction between HER2 receptor status and 
Figure 5 Overall survival and disease-free survival according to HER4 mRNA expression.
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sensitivity to taxanes are not conclusive. However, the 
CALGB 9344 adjuvant study [29] has shown that patients 
with HER2-positive tumors had significant benefit from 
the addition of paclitaxel to doxorubicin/cyclophospha-
mide irrespectively of ER status, while there was no bene-
fit in HER2-negative, ER-positive patients [30]. Moreover, 
a meta-analysis [31] of three trials [30, 32, 33] reported 
a significant interaction between HER2 status and adju-
vant taxane therapy in terms of DFS. Such an interac-
tion could possibly explain (at least in part) the absence 
of negative prognostic significance of HER2 status in the 
current analysis.
In our previous study [7] a positive association 
between HER3 mRNA expression and OS was reported. 
In contrast, no significant association between HER3 
mRNA expression and clinical outcome was found in 
the present analysis. However, HER3 mRNA expression 
was associated with several favorable clinicopathologi-
cal parameters such as ER and PgR positivity, histologi-
cal grade I/II and fewer positive nodes. The available 
data in the literature regarding the prognostic role of 
HER3 in patients with breast cancer are contradictory 
[34]. Although a number of studies support a negative 
prognostic value of HER3 [25, 35, 36], other reports 
suggest a positive prognostic value [24, 37, 38]. So far, 
a conclusive explanation for the discrepancies among 
studies concerning the prognostic value of HER3 
expression in breast cancer cannot be given. Recent 
data indicate that the sub-cellular distribution of HER 
receptors considerably affects their biological activities 
[39]. Therefore, the effect of HER3 on clinical outcome 
may be better evaluated taking into consideration, not 
only the expression of HER3, but also the sub-cellular 
distribution of the receptor and the expression levels of 
HER3 ligands [40].
In complete agreement with our previously reported 
results [7], an association of high HER4 mRNA expres-
sion (using the median value as a cut-off point) with 
increased OS and DFS was found. However, the positive 
prognostic value of high HER4 mRNA expression was 
not maintained in the multivariate analysis. Similarly, 
other studies have also demonstrated the positive prog-
nostic ability of HER4 in patients with breast cancer, both 
at the mRNA and the protein level [24, 25, 41]. Existing 
evidence suggests that HER4 signaling promotes the dif-
ferentiation and inhibition of growth in breast cancer 
cells [42]. In cell line experiments, when HER2-positive 
cancer cells were transfected to overexpress HER4, a 
reduction in proliferation and an increase in apoptosis 
was noted [43].
Table 5 Cox regression multivariate analysis
Missing data, regarding adjuvant hormonal therapy, resulted in a smaller number of patients included in the multivariate analysis for overall survival compared to 
disease-free survival.
Significant p values are shown in bold.
CI confidence interval.
Disease‑free survival (N = 633) Hazard ratio 95% CI Wald’s p
Number of positive nodes
 ≥4 vs. 1–3 2.13 1.58–2.87 <0.001
Type of surgery
 Mastectomy vs. breast-conserving surgery 1.49 1.07–2.06 0.017
Tumor size
 >2 vs. ≤2 cm 1.31 0.94–1.82 0.11
EGFR protein expression
 Positive vs. negative 1.56 1.09–2.24 0.015
Overall survival (N = 612) Hazard ratio 95% CI Wald’s p
Number of positive nodes
 ≥4 vs. 1–3 2.74 1.86–4.04 <0.001
Type of surgery
 Mastectomy vs. breast-conserving surgery 1.48 0.98–2.24 0.066
Tumor size
 >2 vs. ≤2 cm 1.60 1.07–2.40 0.023
Adjuvant hormonal therapy
 Yes vs. no 0.70 0.48–1.04 0.074
EGFR protein expression
 Positive vs. negative 1.66 1.06–2.60 0.028
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With regard to the prognostic potential of the com-
bined expression patterns of the different HER family 
members, our findings indicate that it may be the co-
expression patterns, rather than the expression of indi-
vidual HER family receptors, that should be taken into 
account when assessing the prognosis of patients with 
breast cancer. This observation may prove to have impor-
tant therapeutic implications.
Conclusions
The  present study suggests that EGFR protein overex-
pression, as assessed by IHC, is a negative prognostic fac-
tor for OS and DFS in patients with high-risk operable 
breast cancer. In addition, high HER4 mRNA expression 
was associated with a better clinical outcome in terms 
of OS and DFS in the univariate analysis. Since the clini-
cal study was conducted in the pre-trastuzumab era, the 
above findings appear to have purely prognostic and not 
predictive significance. Furthermore, qRT-PCR may be 
a valid alternative technique for the determination of 
co-expression patterns of HER family receptors in FFPE 
breast tumor samples with possible important therapeu-
tic implications.
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